Johan Rockberg

Professor at KTH Royal Institute of Technology

Speaker

Professor in directed evolution and antibody technology at KTH Royal Inst. Technology, Sweden. Director of GeneNova, a center focused on developing platforms for more cost effective, safe and efficacious AAV based gene therapy through interdisciplinary industry and academia collaborations. He is an expert in protein and cell line engineering with 19000 citations and 55+ publications. Co-PI of human protein atlas program cataloging all human proteins. Co-founder five of companies including StrikePharma AB (Uppsala) developing cancer vaccine, Abclon (Seoul, SouthKorea) developing CAR-T and immunotherapy. Elected member of the Swedish Young Academy (SUA) and Royal Academy of Science (KVA) research policy committee.